XOMA.O Stock Overview
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
XOMA Royalty Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$25.44 |
52 Week High | US$25.85 |
52 Week Low | US$20.43 |
Beta | 0.93 |
11 Month Change | 0.76% |
3 Month Change | 1.76% |
1 Year Change | 5.82% |
33 Year Change | 1.72% |
5 Year Change | n/a |
Change since IPO | 3.08% |
Recent News & Updates
Recent updates
Shareholder Returns
XOMA.O | US Biotechs | US Market | |
---|---|---|---|
7D | 1.2% | 0.2% | -2.1% |
1Y | 5.8% | 12.5% | 19.0% |
Return vs Industry: XOMA.O underperformed the US Biotechs industry which returned 12.5% over the past year.
Return vs Market: XOMA.O underperformed the US Market which returned 19% over the past year.
Price Volatility
XOMA.O volatility | |
---|---|
XOMA.O Average Weekly Movement | 1.5% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: XOMA.O has not had significant price volatility in the past 3 months.
Volatility Over Time: XOMA.O's weekly volatility (1%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1981 | 13 | Owen Hughes | xoma.com |
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
XOMA Royalty Corporation Fundamentals Summary
XOMA.O fundamental statistics | |
---|---|
Market cap | US$326.58m |
Earnings (TTM) | -US$45.08m |
Revenue (TTM) | US$5.81m |
57.3x
P/S Ratio-7.4x
P/E RatioIs XOMA.O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
XOMA.O income statement (TTM) | |
---|---|
Revenue | US$5.81m |
Cost of Revenue | US$122.00k |
Gross Profit | US$5.69m |
Other Expenses | US$50.77m |
Earnings | -US$45.08m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.87 |
Gross Margin | 97.90% |
Net Profit Margin | -775.86% |
Debt/Equity Ratio | 146.6% |
How did XOMA.O perform over the long term?
See historical performance and comparison